Resource Summary Report

Generated by dkNET on Sep 2, 2026

SK-OV-3

RRID:CVCL_0532
Type: Cell Line

Proper Citation

RRID:CVCL_0532

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0532

Proper Citation: RRID:CVCL_0532

Description: Cell line SK-OV-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian serous cystadenocarcinoma

Defining Citation: PMID:327080, PMID:833871, PMID:1423261, PMID:1892748, PMID:2041050, PMID:2653399, PMID:3335022, PMID:3518877, PMID:3804493, PMID:4016745, PMID:6582512, PMID:7459858, PMID:7718330, PMID:8557231, PMID:9041185, PMID:9331090, PMID:9554442, PMID:9698466, PMID:10318951, PMID:10700174, PMID:10972993, PMID:11416159, PMID:11565033, PMID:11789735, PMID:11793438, PMID:12080474, PMID:12417041, PMID:12960427, PMID:15748285, PMID:16380993, PMID:17088437, PMID:17726699, PMID:19372543, PMID:20164919, PMID:20204287, PMID:20215515, PMID:21912889, PMID:22068913, PMID:22328975, PMID:22336246, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22585861, PMID:22628656, PMID:22705003, PMID:22710073, PMID:23415752, PMID:23839242, PMID:23856246, PMID:23933261, PMID:24023729, PMID:24279929, PMID:24434149, PMID:24670534, PMID:25230021, PMID:25485619, PMID:25846456, PMID:25877200, PMID:25984343, PMID:26169745, PMID:26589293, PMID:26668597, PMID:26925792, PMID:27235858, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28196595, PMID:28273451, PMID:30485824, PMID:30894373, PMID:31068700, PMID:31733513, PMID:32612269, PMID:33519462, PMID:35839778, PMID:38861359

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia -

CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-OV-3

Synonyms: SKOV-3, SK-OV3, SK.OV.3, SKOV3, Skov3, SKO3, SKOV3 (S)

Cross References: BTO:BTO_0000948, CLO:CLO_0009063, EFO:EFO_0002340, MCCL:MCC:0000431, CLDB:cl4354, CLDB:cl4355, CLDB:cl4356, AddexBio:C0017008/5024, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-77, BCRJ:0409, BioGRID_ORCS_Cell_line:372, BioSample:SAMN03471310, BioSample:SAMN05292466, BioSample:SAMN10987874, cancercelllines:CVCL_0532, CancerTools:161938, CCRID:1101HUM-PUMC000027, CCRID:3101HUMTCHu185, CCRID:4201HUM-CCTCC00114, CCTCC:GDC0114, Cell_Model_Passport:SIDM00079, ChEMBL-Cells:CHEMBL3307746, ChEMBL-Targets:CHEMBL614925, CLS:300342, Cosmic:687925, Cosmic:688110, Cosmic:755846, Cosmic:809115, Cosmic:844348, Cosmic:849611, Cosmic:875858, Cosmic:897436, Cosmic:897739, Cosmic:905959, Cosmic:906578, Cosmic:920359, Cosmic:923106, Cosmic:924150, Cosmic:927563, Cosmic:932983, Cosmic:947358, Cosmic:948289, Cosmic:949228, Cosmic:991320, Cosmic:1044243, Cosmic:1057759, Cosmic:1066218, Cosmic:1070900, Cosmic:1071897, Cosmic:1092635, Cosmic:1093556, Cosmic:1102817, Cosmic:1113276, Cosmic:1129658, Cosmic:1139226, Cosmic:1175886, Cosmic:1176622, Cosmic:1305333, Cosmic:1312193, Cosmic:1312359, Cosmic:1436037, Cosmic:1482526, Cosmic:1523762, Cosmic:1524361, Cosmic:1707561, Cosmic:1708388, Cosmic:1709249, Cosmic:1998478, Cosmic:2301586, Cosmic:2464670, Cosmic:2560252, Cosmic:2582807, Cosmic:2668296, Cosmic-CLP:905959, DepMap:ACH-000811, ECACC:91091004, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905959, GEO:GSM2110, GEO:GSM50223, GEO:GSM50287, GEO:GSM183338, GEO:GSM183341, GEO:GSM274701, GEO:GSM313702, GEO:GSM459638, GEO:GSM459643, GEO:GSM459644, GEO:GSM459645, GEO:GSM659405, GEO:GSM711713, GEO:GSM743478, GEO:GSM743500, GEO:GSM750833, GEO:GSM784565, GEO:GSM799368, GEO:GSM799431, GEO:GSM827322, GEO:GSM847159, GEO:GSM851940, GEO:GSM887598, GEO:GSM888681, GEO:GSM1001423, GEO:GSM1001424, GEO:GSM1001486, GEO:GSM1153439, GEO:GSM1181272, GEO:GSM1181301, GEO:GSM1291150, GEO:GSM1340593, GEO:GSM1374883, GEO:GSM1670455, GEO:GSM2124684, GEO:GSM2475005, IARC_TP53:21123, ICLC:HTL01014, IGRhCellID:SKOV3, IZSLER:BS TCL 84, KCB:KCB 200810YJ, KCLB:30077, LiGeA:CCLE_824, LINCS_HMS:50044, LINCS_LDP:LCL-1517, Lonza:133, NCBI_Iran:C209, NCI-DTP:SK-OV-3, PharmacoDB:SKOV3_1411_2019, PRIDE:PXD001402, PRIDE:PXD003539, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD007615, PRIDE:PXD030304, Progenetix:CVCL_0532, PubChem_Cell_line:CVCL_0532, SKY/M-FISH/CGH:1438, Wikidata:Q50432263

ID: CVCL_0532

Record Creation Time: 20220427T221547+0000

Record Last Update: 20260829T235939+0000

Ratings and Alerts

No rating or validation information has been found for SK-OV-3.

Warning: Discontinued: ICLC; HTL01014
Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 5055 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. Cancer research, 86(5), 1252.

Azam Z, et al. (2026) Doppel as an early-stage biomarker promoting EMT and dissemination in ovarian cancers. International journal of cancer, 158(6), 1755.

Reed SJ, et al. (2026) Junction opener enables CAR T cell treatment of solid tumors. Scientific reports, 16(1).

Feng L, et al. (2026) Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(19), e21279.

Huang B, et al. (2026) The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. Cell death & disease, 17(1), 202.

Vavers E, et al. (2026) Simultaneous Expression of Sigma-1 Receptor and Tetraspanins Highlights Pathways of Receptor Sorting Into Extracellular Vesicles. Journal of neurochemistry, 170(4), e70426.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. Cancer research, 86(8), 1956.

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. Science advances, 12(16), eaeb0855.

Wang X, et al. (2026) Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine, 7(7), 102885.

Watlington WK, et al. (2026) Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. Molecular oncology.

Bradai N, et al. (2026) LC-ESI-MS/MS Characterization and Biological Activities of Ethyl Acetate and n-Butanol Fractions of Chrysanthemum macrocarpum From Algeria. Chemistry & biodiversity, 23(7), e71454.

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. Frontiers in immunology, 17, 1805950.

Zhang H, et al. (2026) Aptamer targeting HMGB1 attenuates inflammatory disease via domain-specific antagonism. Cell chemical biology.

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. Materials today. Bio, 37, 102924.

Mohiuddin TM, et al. (2026) Synthetic zipper mediated pre-targeting system for near-infrared photoimmunotherapy. iScience, 29(2), 114558.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. Cancer research communications, 6(2), 383.

Zhang J, et al. (2026) Gemcitabine activates the Hippo signaling pathway and suppresses tumor growth by stabilizing large tumor suppressor kinase 2 through the hypoxia-inducible factor 1-alpha/ubiquitin protein ligase E3 component N-recognin 5 axis. Journal of cell communication and signaling, 20(2), e70085.

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. Cell reports methods, 101515.

Rivera M, et al. (2026) APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. Scientific reports, 16(1), 5194.

Ma Y, et al. (2026) Large-Scale Quantitative Morphometry of Platelet ??-Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(34), e75094.